Metrics

Valuation  
Market cap $ 883.922M
Market cap (USD) —
P/E 16.38
PEG —
P/BV 3.05
P/S —
P/OCF 16.45
P/FCF 3.71
Dividend yield —
Turnover / mcap —
Returns  
ROE 44.8%
ROI 65.9%
ROIC -1.8%
Profit margin 98.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 107.464M 64.381M 57.424M 51.346M 55.311M 71.857M 73.414M 60.37M 15.386M 48.648M 42.126M 11.688M 226K
Net profit 105.895M -56.418M -55.193M 872.132M -199.426M -278.017M -236.455M -215.524M -285.405M -190.669M -182.219M -237.038M -156.284M
Free cash flow 238.499M -11.867M -29.485M -187.563M -211.264M -257.019M -241.373M -120.107M -203.458M -101.124M -171.504M -178.262M -123.693M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 18.71 9.41 11.24 11.22 11.05 17.77 25.89 25.59 27.89 31.88 16.39 14.92 —
Price performance 12m 0.99 -0.16 0 0.02 -0.38 -0.31 0.01 -0.08 -0.13 0.95 0.1 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) held an extraordinary general meeting on September 18, 2026 (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, the Company’s shareholders were asked to consider and vote on three proposals related to the Agreement and Plan of Merger, dated as of June 28, 2026 (as it may be amended, supplemented and restated from time to time, the “Merger Agreement”), by and among the Company, Zymeworks Inc., a Delaware corporation (“Parent”), and Zymeworks Merger Sub 1, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub”), each of which is described in further detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) and first mailed to shareholders on or about August 21, 2026 (as amended and supplemented, the “Definitive Proxy Statement”).

(b) and (e)

On June 19, 2026, Theravance Biopharma Ireland Limited, a subsidiary of the Registrant Theravance Biopharma, Inc. (together, the “Company”), entered into a compromise agreement (the “Compromise Agreement”) with Áine Miller, the Company’s Senior Vice President, Development and Head of Ireland Office, pursuant to which Dr. Miller’s employment with the Company will terminate (the “Termination”) on November 15, 2026 (the “Termination Date”) in connection with the restructuring announced by the Company in March 2026 (the “Restructuring”). The Compromise Agreement provided for compensation and other terms consistent with the Employment Agreement entered into between Dr. Miller and the Company on February 10, 2020, as amended on February 8, 2026. In connection with the Termination, the Company also entered into a pension side letter (the “Side Letter”) with Dr. Miller, pursuant to which the Company will make a special contribution for the benefit of Dr. Miller in the amount of $250,000 within 30 days of the Termination Date.

On June 19, 2026, Dr. Miller received a grant of 18,750 restricted share units. The grant was made in connection with Dr.

The 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) of Theravance Biopharma, Inc. (the “Company”) was held on June 12, 2026. Shareholders holding 47,059,878 ordinary shares, representing 91.4% of the total number of shares outstanding and entitled to vote at the Annual Meeting, were present in person or by proxy at the Annual Meeting, which constituted a quorum to conduct business.

The matters voted on at the Annual Meeting are summarized below, and the votes cast with respect to each such matter are set forth below. These matters are described in more detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2026.

Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company’s Annual General Meeting held in 2027 and until their successors are duly elected and qualified:

Nominees For Against Abstain Broker Non-Votes Laurie Smaldone Alsup 42,725,649 124,187 53,867 4,156,175 Susannah Gray 42,231,530 618,306 53,867 4,156,175 Dean J.

Prompts

Theravance Biopharma, Inc. (ticker TBPH), listed in United States.

Company History

Date Change Detail
Aug 11, 2026 Acquired by Acquired by Zymeworks Inc. (CIK 1937653).

ETFs Holding Theravance Biopharma, Inc.

ETF Weight in ETF Shares Market value As of
JSML 0.61% 131,211 $ 2.212M Jul 31, 2026
FSML 0.07% 5,514 $ 93.738K Jun 30, 2026
FEAC 0.05% 811 $ 13.787K Jun 30, 2026
PSC 0.04% 53,416 $ 908.072K Jun 30, 2026
RESM 0.04% 83 $ 1,411.00 Jun 30, 2026
FESM 0.03% 105,010 $ 1.785M Jun 30, 2026
MSSM 0.00% 1,267 $ 21.59K Aug 31, 2026